A novel applicator for low-dose-rate brachytherapy of gynecological cancers

Aaron Wolfson, X. Wu, Cristiane Takita, H. Shao, C. Luo, M. Watzich, D. Diaz, G. R. Walker, V. T. Patino-Flynn, Arnold Markoe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The standard low-dose-rate (LDR) delivery system utilized in the definitive management of patients with cervical carcinoma involves an intrauterine tandem and a pair of vaginal colpostats (ovoids). This well-known application system may deliver inadequate dosage if the tumor extends to the lower vaginal mucosa. During the gauze packing of the ovoids, either operator error or narrowing of the vaginal apex can result in mal-alignment of the colpostats and subsequent inadequate dosing to the ecto-cervix. A novel vaginal cylinder has been designed to address these concerns. Beginning January 1, 2001, patients with cancer of the cervix, endometrium, or vagina requiring LDR brachytherapy have been enrolled into an institutionally sanctioned clinical trial. As of May 31, 2001, a total of 11 patients have been entered but only 10 were successfully implanted with the test device. Patient follow-up has ranged from 0.81 years to 1.2 years (median: 0.96 years). Using our study applicator, all patients received within 10% of the preimplant prescribed dose to tumor. Also, no one had cumulative dosage that exceeded 10% of the maximum allowed dose to the critical normal tissues. Thus far, all study patients have had no clinical evidence of persistence/recurrence of disease or complications from treatment. The preliminary results presented herein clearly demonstrate the feasibility of this novel LDR vaginal cylinder in the treatment of a variety of clinical situations involving gynecological cancers. Our institutional trial is continuing.

Original languageEnglish
Pages (from-to)532-540
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume13
Issue number4
DOIs
StatePublished - Jul 1 2003

Fingerprint

Brachytherapy
Neoplasms
Vaginal Neoplasms
Endometrial Neoplasms
Cervix Uteri
Uterine Cervical Neoplasms
Mucous Membrane
Clinical Trials
Carcinoma
Recurrence
Equipment and Supplies
Therapeutics

Keywords

  • Gynecologic cancers
  • Intracavitary applicators
  • LDR brachytherapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

A novel applicator for low-dose-rate brachytherapy of gynecological cancers. / Wolfson, Aaron; Wu, X.; Takita, Cristiane; Shao, H.; Luo, C.; Watzich, M.; Diaz, D.; Walker, G. R.; Patino-Flynn, V. T.; Markoe, Arnold.

In: International Journal of Gynecological Cancer, Vol. 13, No. 4, 01.07.2003, p. 532-540.

Research output: Contribution to journalArticle

Wolfson, Aaron ; Wu, X. ; Takita, Cristiane ; Shao, H. ; Luo, C. ; Watzich, M. ; Diaz, D. ; Walker, G. R. ; Patino-Flynn, V. T. ; Markoe, Arnold. / A novel applicator for low-dose-rate brachytherapy of gynecological cancers. In: International Journal of Gynecological Cancer. 2003 ; Vol. 13, No. 4. pp. 532-540.
@article{001b10f0663945f28e6808963cfb6aee,
title = "A novel applicator for low-dose-rate brachytherapy of gynecological cancers",
abstract = "The standard low-dose-rate (LDR) delivery system utilized in the definitive management of patients with cervical carcinoma involves an intrauterine tandem and a pair of vaginal colpostats (ovoids). This well-known application system may deliver inadequate dosage if the tumor extends to the lower vaginal mucosa. During the gauze packing of the ovoids, either operator error or narrowing of the vaginal apex can result in mal-alignment of the colpostats and subsequent inadequate dosing to the ecto-cervix. A novel vaginal cylinder has been designed to address these concerns. Beginning January 1, 2001, patients with cancer of the cervix, endometrium, or vagina requiring LDR brachytherapy have been enrolled into an institutionally sanctioned clinical trial. As of May 31, 2001, a total of 11 patients have been entered but only 10 were successfully implanted with the test device. Patient follow-up has ranged from 0.81 years to 1.2 years (median: 0.96 years). Using our study applicator, all patients received within 10{\%} of the preimplant prescribed dose to tumor. Also, no one had cumulative dosage that exceeded 10{\%} of the maximum allowed dose to the critical normal tissues. Thus far, all study patients have had no clinical evidence of persistence/recurrence of disease or complications from treatment. The preliminary results presented herein clearly demonstrate the feasibility of this novel LDR vaginal cylinder in the treatment of a variety of clinical situations involving gynecological cancers. Our institutional trial is continuing.",
keywords = "Gynecologic cancers, Intracavitary applicators, LDR brachytherapy",
author = "Aaron Wolfson and X. Wu and Cristiane Takita and H. Shao and C. Luo and M. Watzich and D. Diaz and Walker, {G. R.} and Patino-Flynn, {V. T.} and Arnold Markoe",
year = "2003",
month = "7",
day = "1",
doi = "10.1046/j.1525-1438.2003.13012.x",
language = "English",
volume = "13",
pages = "532--540",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A novel applicator for low-dose-rate brachytherapy of gynecological cancers

AU - Wolfson, Aaron

AU - Wu, X.

AU - Takita, Cristiane

AU - Shao, H.

AU - Luo, C.

AU - Watzich, M.

AU - Diaz, D.

AU - Walker, G. R.

AU - Patino-Flynn, V. T.

AU - Markoe, Arnold

PY - 2003/7/1

Y1 - 2003/7/1

N2 - The standard low-dose-rate (LDR) delivery system utilized in the definitive management of patients with cervical carcinoma involves an intrauterine tandem and a pair of vaginal colpostats (ovoids). This well-known application system may deliver inadequate dosage if the tumor extends to the lower vaginal mucosa. During the gauze packing of the ovoids, either operator error or narrowing of the vaginal apex can result in mal-alignment of the colpostats and subsequent inadequate dosing to the ecto-cervix. A novel vaginal cylinder has been designed to address these concerns. Beginning January 1, 2001, patients with cancer of the cervix, endometrium, or vagina requiring LDR brachytherapy have been enrolled into an institutionally sanctioned clinical trial. As of May 31, 2001, a total of 11 patients have been entered but only 10 were successfully implanted with the test device. Patient follow-up has ranged from 0.81 years to 1.2 years (median: 0.96 years). Using our study applicator, all patients received within 10% of the preimplant prescribed dose to tumor. Also, no one had cumulative dosage that exceeded 10% of the maximum allowed dose to the critical normal tissues. Thus far, all study patients have had no clinical evidence of persistence/recurrence of disease or complications from treatment. The preliminary results presented herein clearly demonstrate the feasibility of this novel LDR vaginal cylinder in the treatment of a variety of clinical situations involving gynecological cancers. Our institutional trial is continuing.

AB - The standard low-dose-rate (LDR) delivery system utilized in the definitive management of patients with cervical carcinoma involves an intrauterine tandem and a pair of vaginal colpostats (ovoids). This well-known application system may deliver inadequate dosage if the tumor extends to the lower vaginal mucosa. During the gauze packing of the ovoids, either operator error or narrowing of the vaginal apex can result in mal-alignment of the colpostats and subsequent inadequate dosing to the ecto-cervix. A novel vaginal cylinder has been designed to address these concerns. Beginning January 1, 2001, patients with cancer of the cervix, endometrium, or vagina requiring LDR brachytherapy have been enrolled into an institutionally sanctioned clinical trial. As of May 31, 2001, a total of 11 patients have been entered but only 10 were successfully implanted with the test device. Patient follow-up has ranged from 0.81 years to 1.2 years (median: 0.96 years). Using our study applicator, all patients received within 10% of the preimplant prescribed dose to tumor. Also, no one had cumulative dosage that exceeded 10% of the maximum allowed dose to the critical normal tissues. Thus far, all study patients have had no clinical evidence of persistence/recurrence of disease or complications from treatment. The preliminary results presented herein clearly demonstrate the feasibility of this novel LDR vaginal cylinder in the treatment of a variety of clinical situations involving gynecological cancers. Our institutional trial is continuing.

KW - Gynecologic cancers

KW - Intracavitary applicators

KW - LDR brachytherapy

UR - http://www.scopus.com/inward/record.url?scp=10744220332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220332&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.2003.13012.x

DO - 10.1046/j.1525-1438.2003.13012.x

M3 - Article

C2 - 12911734

AN - SCOPUS:10744220332

VL - 13

SP - 532

EP - 540

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -